Down the line from genome-wide association studies in inflammatory bowel disease:the resulting clinical benefits and the outlook for the future by Spekhorst, Lieke M. et al.
  
 University of Groningen
Down the line from genome-wide association studies in inflammatory bowel disease
Spekhorst, Lieke M.; Visschedijk, Marijn C.; Weersma, Rinse K.; Festen, Eleonora Anna
Published in:
Expert review of clinical immunology
DOI:
10.1586/1744666X.2015.990439
IMPORTANT NOTE: You are advised to consult the publisher's version (publisher's PDF) if you wish to cite from
it. Please check the document version below.
Document Version
Final author's version (accepted by publisher, after peer review)
Publication date:
2015
Link to publication in University of Groningen/UMCG research database
Citation for published version (APA):
Spekhorst, L. M., Visschedijk, M. C., Weersma, R. K., & Festen, E. A. (2015). Down the line from genome-
wide association studies in inflammatory bowel disease: the resulting clinical benefits and the outlook for
the future. Expert review of clinical immunology, 11(1), 33-44. [25493555].
https://doi.org/10.1586/1744666X.2015.990439
Copyright
Other than for strictly personal use, it is not permitted to download or to forward/distribute the text or part of it without the consent of the
author(s) and/or copyright holder(s), unless the work is under an open content license (like Creative Commons).
Take-down policy
If you believe that this document breaches copyright please contact us providing details, and we will remove access to the work immediately
and investigate your claim.
Downloaded from the University of Groningen/UMCG research database (Pure): http://www.rug.nl/research/portal. For technical reasons the
number of authors shown on this cover page is limited to 10 maximum.
Download date: 12-11-2019
Down the line from
genome-wide association
studies in inflammatory
bowel disease: the resulting
clinical benefits and the
outlook for the future





1Department of Gastroenterology and
Hepatology, University of Groningen
and University Medical Centre
Groningen, 9700 RB Groningen,
The Netherlands
2Department of Genetics, University of
Groningen and University Medical





Inflammatory bowel disease (IBD), consisting of Crohn’s disease and ulcerative colitis, is a
chronic inflammatory disease of the gut. The etiology of IBD is complex, involving genetic as
well as environmental factors. Genetic studies have identified 163 genetic risk loci for IBD,
which have led to new insights into the biological mechanisms of the disease. The currently
known IBD risk loci show an almost 75% overlap with genetic risk loci for other immune
mediated diseases. Current studies are focused on the translation of the identified risk loci to
clinical practice. The first steps towards this translation are being taken with the identification
of genetic risk factors for drugs toxicity, specific disease course and response to therapy. In
this review we will discuss how the IBD genetic risk loci were identified and how this
knowledge can be translated towards clinical practice.
KEYWORDS: crohn’s disease . drug targets . GWAS . immune mediated diseases . immunochip . inflammatory bowel
disease . risk models . ulcerative colitis
Inflammatory bowel disease (IBD) is a chronic
immune mediated disease affecting the gastro-
intestinal tract. The prevalence of IBD in the
Western World, is approximately 1 in
1000 individuals and there is an increasing
trend in incidence and prevalence in develop-
ing countries [1]. IBD consists of two distinct
diseases; Crohn’s disease (CD) and ulcerative
colitis (UC), which have some overlapping
clinical and pathological features. In CD the
inflammation can occur throughout the entire
gastro-intestinal tract, the inflammation can
affect all mucosal layers and can be compli-
cated by strictures, and formation of abscesses
and fistula. In UC the inflammation is limited
to the colon and only affects the upper muco-
sal layer. Formation of abscesses and fistula
does generally not occur in UC and stenosis is
a very rare complication in UC [2,3].
IBD is a complex disease, meaning that its
aetiology is multifactorial: genetic, epigenetic
and environmental factors interact and give
rise to the disease. Environmental factors like
smoking, medication, appendectomy, exposure
to pollution, and diet have been implicated to
play an essential role in the pathogenesis of
IBD [4]. Smoking and prior appendectomy
have been proven to be protective in UC, but
in contrast smoking can aggravate inflamma-
tion in CD and increase the risk for CD [5].
The composition of the gut micriobiota, is
also likely to be a major factor in IBD disease
pathogenesis [6–9].
Over the preceding decades, co-occurrence
and familial aggregation of IBD was observed
indicating that IBD has a strong hereditary
component [10]. As the field of genetic research
evolved rapidly it revealed new insights into
pathogenesis of IBD. Initially genetic linkage
studies were performed in families with an
extremely high prevalence of IBD, which led
to the identification of the first genetic risk
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locus for IBD, containing the gene NOD2 [11–13]. As genome-
wide-associations studies (GWAS) became available, hypothesis-
free testing of common genetic variants for association to
disease became possible [14]. GWAS were very successful in
IBD: within four years 99 genetic risk loci for IBD had been
identified, making it the most successfully GWA studied
immune-mediated disease [15]. Subsequently a new genotyping
chip was designed which targeted areas on the genome likely to
play a role in immune mediated disease: the Immunochip.
Again this effort has been very successful in IBD: 163 genetic
risk loci have been identified to date [16].
The genetic risk loci identified for IBD so far have shed new
light on the biological pathways underlying the disease. The
translation of all of this knowledge on the genetic background of
IBD towards clinical practice is still difficult. The steps from
GWAS identified genetic disease risk variants to clinical practice
are outlined in FIGURE 1. Currently projects are being undertaken
to clarify the exact effect of genetic risk variants on the pheno-
typic variation seen in IBD. A better understanding of how
genetic risk variants lead to different disease phenotypes can help
us predict disease course per individual, which in turn can help
us determine the most adequate treatment for each individual.
In this review we will first consider the clinical aspects of
IBD. We will then highlight the new insights that GWAS and
the Immunochip have brought us for IBD. We will discuss the
overlap between IBD genetic risk loci and their underlying bio-
logical pathways and the genetic risk loci and pathways for
other immune mediated diseases. Finally, we will discuss how
these pathways can be used for therapeutic targeting and how
this can help pave the way towards ‘personalized medicine’.
The clinical presentation of IBD
IBD is a chronic mucosal inflammatory disease of the gastro-
intestinal tract, characterized by periods of remission and
relapse. Because of this dynamical character of the disease,
patients can experience severe symptoms during an exacerba-
tion, while symptoms can be mild or absent during remission.
Active IBD can cause symptoms like abdominal discomfort,
diarrhoea, weight loss, rectal bleeding and fatigue. In addition
to inflammation of the gut, 25% of the patients have extra-
intestinal manifestations (EIM). Arthralgia is the most common
EIM, but ophthalmological and primary mucocutaneous EIMs
are also common [2,17,18]. Direct disease symptoms and EIMs
influence psychosocial functioning and might result in a signifi-
cantly lower quality of life and loss of work productivity [19,20].
Disease remission can be induced and sustained by medical
treatment such as mesalazine, corticosteroids, and immunosup-
pressants like azathioprine and anti-TNF antibody therapies [21].
Nevertheless, up to 20% of the UC patients and almost 50%
of the CD patients will need surgery within 10 years after diag-
nosis because of refractory disease, fibrostenotic disease, compli-
cations or development of colorectal carcinoma [22].
IBD therapy is complicated by the fact that IBD is a hetero-
geneous disease with a variety of clinical phenotypes, each of
which require specific treatment. Currently the treatment para-
digm of IBD is shifting from treating symptomatic patients (the
‘step-up’ approach) to starting intensified treatment regimens
early in the disease to prevent complicated disease behaviour
and flares of the disease (the ‘top-down’ approach) [23]. Before
starting this top-down treatment it is essential to select those
patients at risk for severe disease, to avoid high costs, ‘over
treating’ and potentially severe side effects. At this moment one
of the major issues that clinicians face is the selection of these
patients at risk for a severe disease course. There are no clinical
parameters or biomarkers which predict how the disease will
develop, so selecting these high-risk patients is complex. Some
known risk factors like early age of onset, familial occurrence of
IBD and extensive disease at presentation are considered to be
predictive for severe disease [24,25]. However, these factors offer a
relatively slim foundation for aggressive treatment with expen-
sive drugs with potentially severe side-effects [26]. Better under-
standing of the influence of environmental, genetic, and
microbiomic factors on IBD phenotype will not only improve
choice of treatment for IBD patients but will also enhance our
understanding of the underlying disease mechanisms.
Genetic studies prior to the genome wide association
scans
As mentioned previously, family studies showed that genetic
factors play an important role in IBD risk: the occurrence of
CD and UC in first-degree family members is respectively
10-fold and 4-fold higher compared to the general population
and in monozygotic twins the concordance of CD and UC is
respectively 30 and 15% [10].
The first genetic studies in IBD were linkage and candidate









Figure 1. The steps leading from findings of genome-wide
association studies (GWAS) to clinically significant
outcomes. From bottom to top: In red: GWAS identify single
nucleotide polymorphisms (SNPs) that are associated to the dis-
ease. In orange: the next challenge is the identification of the
gene that correlates with the associated SNP. In yellow: then
causal variants can be identified that influence the disease associ-
ated genes. In green: once it is known which genes are involved
in the disease underlying disease pathways can be constructed
through co-expression and protein-protein interaction analysis. In
blue: finally different genetic backgrounds can be identified that
lead to slightly different disease mechanisms resulting in diverse
disease phenotypes.
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by testing a series of marker alleles for co-segregation (linkage)
with disease status through different generations in a family. In
candidate gene association studies a candidate gene is selected
based on what is known about the disease mechanism. This
gene is then tagged with common genetic variants, and tested
for association to a trait. A total of 10 linkage and association
studies for IBD were performed in the period from 1996 to
2004 [27]. Compared to similar studies in Mendelian diseases
the yield of these studies in complex disease might be consid-
ered disappointing. This is mainly caused by the fact that the
effect size of genetic risk variants for complex disease tends to
be much smaller than that for Mendelian disease. Nonetheless,
linkage studies identified the first risk gene for CD: NOD2 on
chromosome 16 [11–13]. In 2001 three low frequency coding
mutations (R702W, G908R and 3020insC) in the NOD2 gene
were found to be independently associated with CD in Cauca-
sian patients [12,13,28]. These three variants lead to odds ratios
(ORs) for CD between 2 and 4 in individuals heterozygote for
the variants, and to ORs between 20 and 40 in individuals
homozygote for the variants. Nowadays NOD2 variants remain
the strongest genetic risk variants for CD.
Alongside NOD2, linkage studies suggested a link between
IBD and three other genetic loci with a lower effect size: the
IBD3 locus (in the HLA-region), the IBD5 locus (containing
SLC22A4, SLC22A5 and other genes), and a locus on chromo-
some 5q31 (containing no genes; a ‘gene desert’) [27].
Genome wide association studies
In the early 2000s tremendous technological advances and the
progress of the Human Genome Project provided the opportu-
nity to perform GWAS [29,30]. GWAS typically focus on
associations between complex traits and 100,000–500,000
single-nucleotide polymorphisms (SNPs), selected to tag a max-
imum of genetic variation over the whole genome. A SNP is a
DNA sequence variation, which occurs commonly in a popula-
tion. A GWAS looks for statistically significant differences in
allele frequencies of these SNPs between a large number of
individuals with disease status (cases) and healthy controls. The
associated SNPs mark genomic loci (which can contain several
genes) in the human genome, which influence the risk of dis-
ease. Unlike linkage studies, GWAS are not restricted to sibling
pairs and families, and thus have more statistical power to
detect genetic risk loci of small to moderate effect sizes. Due to
correction for multiple testing, there is a strict protocol for rep-
lication and the genome-wide statistical significance association
for true positives was set to a P-value <5  108 [31].
The first GWAS study in European ancestry CD patients
confirmed NOD2 as a CD risk gene. Moreover, it identified
the association between CD and a locus containing IL23R,
encoding a pro-inflammatory cytokine, which stimulates T-cells
towards chronic inflammation [32]. The most remarkable path-
way discovered through early CD GWAS studies is the autoph-
agy pathway, which was discovered through associations at loci
containing ATG16L1 and IRGM [33–35]. The early GWAS stud-
ies in UC showed substantial overlap of genetic risk
background with CD (IL23R, IL12B, NKX2-3 en MST1), but
also some UC specific loci (IL10, HLA). NOD2, ATG16L1
and IRGM remain CD specific loci [36–39].
A GWAS typically uses approximately 500–2000 cases and a
similar number of controls genotyped at 100,000–
500,000 SNPs. To increase the power of GWAS to detect
more genetic risk variants a meta-analysis of all previously pub-
lished CD GWAS was performed, which included 3000 cases
and 5000 controls. This meta-analysis confirmed 11 previously
putative loci and helped discover 21 new CD risk loci, includ-
ing loci containing STAT3 and JAK2 [40].
The appreciation of the need to further increase sample sizes
led to increased collaboration through the International IBD
Genetics Consortium (IIBDGC) [41] to bring together investiga-
tors and GWAS datasets from IBD genetics groups around the
world. The IIBDGC published three GWAS meta-analyses
between 2008 and 2011. A CD meta-analysis of six GWAS with
a total sample size of ~50,000 individuals identified 30 new loci,
bringing the total count of CD genetic risk loci to 71 [42].
Similarly a meta-analysis of six GWAS studies in UC with a
sample size of ~17,000 individuals identified 29 new UC loci.
This increased the number of UC genetic risk loci to 47 [15].
These GWAS meta-analyses increased the total number of
confirmed IBD risk loci to 99, including at least 28 shared
association signals between CD and UC.
Immunochip
As GWAS results for other immune mediated diseases fol-
lowed, it became clear that some risk variants were disease-spe-
cific, but that most risk variants were shared between IBD and
various other immune mediated diseases. In 2011 approximately
51 of the thus far identified 99 IBD risk loci turned out to be
shared with 23 different diseases, most of which immune medi-
ated diseases [43,44]. This concept formed the basis for the devel-
opment of the Immunochip: a chip composed of all genetic
variants correlated to immune mediated disease [45,46]. The
Immunochip covers almost 200,000 SNPs for 12 distinct
immune mediated diseases (CD, UC, autoimmune thyroid dis-
ease, ankylosing spondylitis, celiac disease, IgA deficiency, mul-
tiple sclerosis [MS], primary sclerosing cholangitis [PSC],
primary billiairy cirrhosis [PBC], psoriasis, rheumatoid arthritis
[RA], systemic lupus erythematosus [SLE] and Type 1 diabetes
[T1D]). The Immunochip was designed to densely genotype
immune mediated disease risk loci with common genetic var-
iants [45]. The Immunochip project had two main goals. The
first goal was to validate the already identified disease risk loci
and to establish previously putative genetic risk loci as definite
genetic risk loci by testing them in a large number of new cases
and controls, a process termed ‘deep replication’. To achieve
this goal the top ~3000 associated SNPs for each disease
known from GWAS and GWAS meta-analysis were tested in a
large number of case and control samples that had not been
tested in previous GWAS. The second goal of the project was
to fine map each risk locus to identify the most likely focus
of the genetic variant that is actually causal to the disease


































































association. To achieve this goal each known genetic risk locus
was densely covered with SNPs on the Immunochip [46].
The Immunochip, though purposefully designed, has a few
limitations that should be taken into consideration.
First of all, not all loci are densely covered; putative genetic
risk loci are generally only covered by a handful of SNPs. This
means that, especially in the putative loci, the SNP showing
the strongest association to disease is unlikely to be causal, and
more likely to be in ‘linkage disequilibrium’ with the causal
SNP. Linkage disequilibrium means that the most strongly
associated SNP inherits with the causal variant because they are
on a stretch of DNA that does not break during cell replica-
tion. A second limitation of the Immunochip is that it is less
sensitive in non-European ethnic groups, because the SNPs
have been selected from genome reference sets based on indi-
viduals of European origin. A third limitation is that the
Immunochip only includes relatively common genetic variants
(minor allele frequency >0.5%), whereas more rare variants can
confer larger effects on disease risk. A final limitation, inherent
to the design of the Immunochip, is that it does not cover the
whole genome, but only focuses on known immune disease
genetic risk loci [46].
The number of new loci that can be identified with genome
wide significance, that is with confidence that the finding is
not a false positive, depends in part on the sample size and in
part on the allele frequency of the genetic variants tested [47].
The Immunochip project identified 64 new risk loci for IBD
increasing the number of known IBD genetic risk loci to an
impressive number of 163 risk loci. Of these 163 risk loci,
30 are specific for CD and 23 for UC. The other 110 loci are
shared by both diseases, implying that a shared biological
mechanism plays a role in both phenotypes [16]. Whereas the
Immunochip substantially increased the number of known
genetic risk loci for IBD, these risk loci explain only a minority
of the genetic variance in disease risk: 13–13.5% in CD and
7.5–9% in UC [16,48]. The fact that we can only explain such a
small amount of risk variance in IBD suggests that other fac-
tors, like rare risk variants not tagged by the chips used so far,
or interactions between genetic variants and environmental fac-
tors, also play a substantial role in the risk for IBD. Interac-
tions within and between genetics and environment modulate
the risk for a disease. These interactions are still poorly under-
stood, which makes, for example, predicting disease risk with
genetic risk variants complex.
Besides identifying new shared and unshared risk loci for
several immune mediated diseases, the Immunochip also
detected some highly interesting discordant associations, that is,
instances in which a risk locus is shared for two diseases but
where the associated variant conveys risk in one disease and is
protective in the other disease. Some interesting cases of discor-
dant associations are seen between CD and UC. Although the
clinical phenotypes of the diseases are clearly overlapping, and
shared risk loci are thus to be expected, a number of shared
loci were found that showed a risk effect in opposite directions
for each disease. An example is the locus containing the
PTPN22 gene (encoding the protein tyrosine phosphatase) [49].
The main risk variant in this locus, Arg620Trp, increases risk
for UC, but is protective for CD [16,50]. The mechanism under-
lying these discordant associations has not yet been clarified.
Immune mediated diseases
IBD is, as described earlier, a chronic inflammatory disease
caused by an excessive inflammatory reaction to the host’s own
gut microbiome. This makes IBD one of a large range of what
can be termed immune mediated disorders: chronic inflamma-
tory diseases caused by an inflammatory reaction to an antigen
that, in healthy individuals, is tolerated or quickly disposed of.
For some of these diseases the antigen is known, such as the
gluten protein in celiac disease. Celiac disease represents a spe-
cial case of an immune mediated disorder, because the antigen
can be avoided with a gluten-free diet, thereby more or less
‘curing’ the disease. IBD also forms a special case among the
immune mediated diseases: the instigative antigen is generally
assumed to be the commensal flora of the gut. However, unlike
gluten, the commensal flora of the gut is not something one
can avoid. For most other immune mediated disorders, the
instigative antigen is unknown, complicating the unravelling of
the disease mechanism. For RA, ankylosing spondylitis, SLE,
T1D and autoimmune inflammatory disease of the thyroid,
antigens have been proposed but not conclusively proven.
Although each of these diseases have different phenotypes
and might have different instigative antigens they share com-
mon inflammatory pathways. Immune mediated disorders are
known to co-occur within families or even within individuals,
suggesting they also share a common genetic background.
In 2008, early in the GWAS era, results of the different
immune mediated disorders already revealed 23 genetic risk
loci to be shared by two or more immune mediated diseases
(ankylosing spondylitis, asthma, auto-immune thyroid disease,
coeliac disease, MS, psoriasis, RA, SLE, T1D, CD and
UC) [44]. As data accumulated, in 2011 approximately 51 IBD
genes were found to be shared with 23 different diseases,
including immune mediated disorders, infectious diseases and
other gastro-intestinal disorders [43,51]. Noteworthy among these
shared genetic loci are the risk loci that encode proteins from
the adaptive immune system (IL23R, IL10, IL12B, IL27,
IL18RAP), these loci seem to play a role in a shared pathway
for CD, UC and several other immune mediated diseases [43].
The Immunochip once again showed that shared genetic risk
loci might not have the same effect in each disease. Besides
the previously observed correlated and discordant associations
(the same haplotype is protective in one disease but increases
the risk for another disease), it showed association signals that
are non-correlated (different risk haplotypes are seen in shared
risk loci), and association signals that are correlated and
concordant (a risk variant increases the risk for more than one
immune mediated disease) [50]. This phenomenon is called plei-
otropy, meaning that seemingly unrelated phenotypes can be
derived from the same risk variants and that seemingly related
phenotypes can derive from divergent risk variants. The
Review Spekhorst, Visschedijk, Weersma & Festen

































































mechanism underlying this pleiotropy might be that the combi-
nation of different genetic risk variants and environmental fac-
tors determine the immune mediated disease that a patient
will develop.
Almost three-quarters of the IBD loci were found to be over-
lapping with other immune mediated diseases [43,50] and 71 loci
were associated with two or more immune mediated diseases
(IBD, ankylosing spondylitis, coeliac, psoriasis, RA, Type 1
Diabetes). Of these 71 loci 45% resulted in an increased risk,
14% had opposites effects (protective versus risk variant) and
42% shared the same loci but with different risk
haplotypes [50].
Pathogenetic pathways in IBD
GWAS and Immunochip meta-analysis have revealed 163 risk
loci for IBD, most of which are shared for CD and UC and
which identify key regulating pathways for both diseases. To
advance our understanding of the mechanisms underlying dis-
ease we have to carefully select and study candidate gene(s)
within each locus to see how these contribute to disease suscep-
tibility. The most replicated and confirmed loci have been
extensively studied and their candidate genes and their path-
ways reveal possible disease mechanisms for CD and UC also
in functional studies and mouse models.
One of the strongest susceptibility loci in CD is the locus
containing NOD2 [12,13]. NOD2 is located on chromosome
16 and encodes an intracellular pattern-recognition receptor of
the innate immune system [52,53]. This receptor recognizes viral
and microbial components; maintaining the gut mucosal bar-
rier through regulation of microbiome homeostasis and activa-
tion of the innate immune response [54]. One of the
mechanisms through which NOD2 regulates microbiome
homeostasis is by the production of antibacterial defensins [55].
NOD2 receptor signalling against microbial components
depends on its intracellular localization. NOD2 risk variants
cause a disrupted receptor, which make the receptor unable to
recognise intracellular bacteria. This probably leads to dysbiosis
of the intraluminal contents, thereby causing an inappropriate
immune response [13,56,57]. Carriage of two NOD2 risk variants
also increases the risk of a severe CD disease phenotype result-
ing in penetrating and/or sticturing disease [58].
Another important pathway in the disease pathogenesis of
CD that has been discovered through genetic studies is autoph-
agy (ATG16L1, SMURF1, LRRK2 and IRGM) [33,59,60].
Autophagy describes a cellular pathway in which organelles and
foreign proteins are being delivered to the lysosome in the cell
for degradation, which makes it a crucial immune defence
mechanism [61,62]. Moreover there is a functional link between
ATG16L1 and NOD2, as NOD2 recruits ATG16L1 to the
plasma membrane at the bacterial site of invasion to initiate
autophagy. Several risk variants (SNPs), associated with NOD2
and ATG16L1 have been found to affect bacterial autophagy.
This implies that deficient bacterial autophagy plays a key role
in the disease pathogenesis of CD [59,63,64]. The autophagy
related NOD2 and ATG16L1 variants are specific to CD, but
other autophagy related genes are associated with both CD and
UC (SMURF1, LRRK2 and IRGM) [16,65].
The IL23R genetic IBD risk locus is part of an important
disease pathway for IBD: T-helper 17 (Th17) signalling. The
IL23R gene in this locus encodes an IL23 receptor whose sub-
unit interacts with interleukin 23 (IL23) a pro-inflammatory
cytokine. IL23 regulates the immune response against exoge-
nous antigens in the gut, by inflammation through the produc-
tion and differentiation of Th17 lymphocyte cells [66,67].
Mutations or variation in or near the IL23R gene are hypothe-
sized to cause an inappropriate immune response to the com-
mensal flora of the gut [32,68,69]. Loci with genes encoding
proteins with functions downstream in the IL23-Th17 pathway
have also been identified as IBD risk loci. These genes affect
components of the IL23 pathway that are expressed in Th17,
Th1 and other innate lymphoid cells. Among these IBD risk
loci are loci containing JAK2 (Janus kinase 2) and STAT3 (sig-
nal transducer and activator of transcription 3). The activation
of the IL23R at the cell surface activates a secondary intracellu-
lar signalling pathway JAK2/STAT3. This JAK/STAT pathway
plays a role in the innate and adaptive immunity, and particu-
larly in the progression of inflammation in the Th17 cell path-
way [70]. Several genes encoding pro-inflammatory cytokines in
the Th17 pathway, which have been shown to be overexpressed
in IBD, have also been implicated in the genetic background
of IBD: IL22, IL21 and IL26 [71–76].
‘Ten-year’ review: genetic research translated to the
clinic
In this post-GWAS era, our knowledge on the molecular back-
ground of IBD has progressed to such a high level, that an
inevitable and crucial question arises: How do we translate this
knowledge to clinical practice to improve treatment of IBD or
even to detect IBD early and prevent it from progressing to a
full blown inflammatory disease (FIGURE 2) [77]?
Screening individuals at risk
Could we screen the general population for risk of IBD with
the genetic risk variants that have been identified? The answer
is that we could, in theory, but the predictive value of such a
genetic screening test would be very low, because, as mentioned
earlier, the genetic variants identified so far explain less than
20% of the genetic risk for IBD [39,78]. To improve the predic-
tive power of this predictive test by enriching it with environ-
mental risk factors is also not yet feasible, since our knowledge
on environmental risk factors for IBD is still relatively poor. So
screening the general population for IBD risk is not yet possi-
ble. Moreover, one could wonder whether we really should
screen the general population for a disease that we cannot (yet)
prevent. Genetic screening of individuals at high risk for IBD,
for example children from families with a high prevalence of
IBD with the currently known IBD risk loci, is similarly
unlikely to be successful. The currently known genetic risk var-
iants for IBD are genetic variants that are common (minor
allele frequency >1%) in the general population, and hence will


































































not provide a test with a high specificity. Moreover, in families
in which IBD is highly prevalent the underlying genetic risk
variants are likely to be rare variants that may well have not yet
been identified. Finally screening in high-risk individuals would
only be useful if minimally invasive or preventative therapy
such as dietary intervention would be available. Unfortunately,
dietary interventions have not been proven effective in IBD, so
early detection of IBD would only lead to earlier recognition
of disease, followed by standard treatment [79].
Drug development
While our knowledge on the genetic background of IBD can-
not be used for risk prediction, it does provide important
insights into the disease mechanism of IBD. Each genetic risk
locus is a potential drug target for IBD therapy. Before such
targeted drugs can be developed, the target loci have to meet
several important criteria.
The first criterion for the development of targeted drugs is
that the causal variant in the genetic locus has to be known
and the effect of this causal variant on the biological function
of the gene it affects has to be understood [80]. Currently, we
cannot yet meet this criterion: the genetic variants that have
been identified by GWAS are variants with a high prevalence
in the general population. Hence these variants are very suitable
for mapping genetic variance between cases and healthy con-
trols but they are unlikely to have a direct effect on the
function of a gene. This means that the 163 genetic variants
that are associated to IBD are not the true causal genetic var-
iants that affect the genes in these loci but that these 163 var-
iants are correlated to the causal genetic variants in these loci.
Fine-mapping of these genetic risk loci and targeted
re-sequencing of genetic risk loci in large cohorts of IBD cases
and healthy controls is currently being performed and will lead
to better understanding of the causal link between the IBD
associated common genetic variants and the disease
mechanism (FIGURE 1). The translation from common genetic risk
variant to clinically significant output initially involves the
identification of the gene that the variant is likely to be corre-
lated to by gene prioritizing. The causal gene is likely to have a
differential expression as a result of the genetic variant, i.e., by
identifying expression Quantitative Trait Loci (eQTL). The
causal gene might also be identified because it encodes proteins
that are known to interact with proteins known to be involved
in IBD mechanisms, i.e., by protein-protein interaction (PPI) or
through Gene Relationships Across Implicated Loci (GRAIL).
The second criterion for developing targeted drugs is that
the causal genetic variant, or its effect on gene function, is dru-
gable, and that targeting this mechanism does not lead to
adverse events [80]. Some CD risk variants might for example
cause an inadequate innate immune response, but upregulating
this innate immune response with a drug might lead to
increased inflammation caused by an exaggerated innate
immune response. Other CD risk variants are located in gene
deserts where the identification of a drugable candidate gene
might be impossible.
In short, the road from the currently identified IBD genetic
risk variants to the development of new IBD drugs seems long
and hardly cost-effective. In spite of this there are several exam-
ples of approved drugs for which genetic studies identified the
drug target to be associated with IBD, while the drug had
already been developed independently from genetic
knowledge (TABLE 1). Ustekinumab (Janssen-Cilag), a human
antibody against IL-12 and IL-23, has for example been shown
to be effective in the treatment of CD [81,82]. Ustekinumab
blocks binding of IL-12 and IL-23 and thereby blocks the
inflammatory cascade downstream of these interleukins. The
importance of this inflammatory pathway had already been
observed in the genetic background of IBD since IL23R and
IL12B are important risk loci for IBD.
GWAS identified genetic loci containing JAK2, STAT3 and
TYK2 genes as risk loci for IBD. The proteins encoded by
these genes, JAK2, STAT3 and TYK2, play crucial roles in sec-
ondary pro-inflammatory signalling after activation of the
IL23 pathway, as described earlier. Tofacitinib (Pfizer) a selec-
tive JAK-inhibitor seems to be effective in the induction and
maintenance of remission of IBD and is currently being tested
in Phase III trials [83,84].
The autophagy pathway was identified as an important dis-
ease mechanism for CD through the recognition of ATG16L1,
NOD2 and IRGM as CD risk genes. The genetic risk variants




























 for a patient
Figure 2. From genetic risk variants to the clinic. The red
arrows show the interaction of genetic risk variants with other
factors leading to inflammatory bowel disease (IBD) phenotypes.
De blue arrows show the interaction of the non-genetic IBD risk
factors with IBD phenotype. De green arrows show the route
research will have to take down the line from the identification
of genetic risk variants to clinical practice. The square in the
lower right corner of the figure shows how our current knowl-
edge could lead to ‘personalized medicine’ i.e., the best possible
therapy for a patient.
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consequently lead to less efficient disposal of invasive microbes.
Everolimus (Novartis) and Sirolimus (Pfizer) are both mamma-
lian target of rapamycin (mTOR) inhibitors and up-regulate the
autophagy pathway [85,86]. Both drugs are registered for immune
suppression after solid organ transplantation. Because of their
known immunosuppressant effects and their specific effect on the
autophagy pathway the drugs were tested in CD. Although
case-reports of the treatment of CD with Sirolimus seemed
promising, a randomized case-control study with Everolimus was
terminated early because the drug showed no efficacy [85,86]. One
could speculate that in the future such trials should be repeated
but then including only cases with impaired autophagy e.g., car-
rying the ATG16L1, NOD2 or IRGM risk variants.
Finally the homing of leukocytes to the gut seems to be an
interesting disease mechanism since genetic risk loci containing
CCR6 and CXCR5, genes encoding proteins involved in this
process, are associated to IBD [16]. Before this genetic knowl-
edge was available drugs that impede leukocyte migration to
the gut had already been developed. Initial trials of Natalizu-
mab (Biogen), an a-4 integrin inhibitor, showed promising
results for inducing and maintaining remission in CD [87,88].
However serious side-effects were observed: the drug also pre-
vents migration of leukocytes to the central nervous system,
which increases the risk of severe infections of the central ner-
vous system [89]. Vedolizumab (Millennium Pharmaceuticals,
Inc) is a more specific integrin inhibitor: it specifically inhibits
a-4-b-7 receptors, which makes this drug a specific inhibitor
of leukocyte migration to the gut. Vedolizumab was shown to
be effective for induction and short-term maintenance of remis-
sion of disease in UC patients and CD patients with prior fail-
ure on anti-TNF therapy [90–92].
Drug repositioning
As mentioned earlier, developing new drugs targeted on IBD
genetic risk loci will be a long and difficult process. The case
of the testing of the mTOR inhibitors Everolimus and Siroli-
mus in CD however perfectly illustrates an alternative scenario:
identifying alternative or refined indications for existing drugs
approved for other indications. This process, called drug reposi-
tioning, is likely to become an important alternative to classic
drug development because of the increasing costs of the devel-
opment of new drugs and our increasing understanding of the
biological background of diseases. For drug repositioning one
considers the genetic background and biological pathways
involved in a disease and identifies registered drugs or known
investigative new drugs that target these biological pathways.
A new and interesting candidate for drug repositioning in IBD
is Denosumab. Denosumab (Amgen/GlaxoSmithKline) is regis-
tered for prevention of fractures caused by osteoporosis in post-
menopausal women [93,94]. The drug acts through TNFSF11,
encoded by the TNFSF11 gene that has previously been identi-
fied as a risk locus for CD and bone mineral density [42,95].
Predicting drug toxicity
Already important discoveries have been made in identifying
genetic variants that predict drug toxicity. Variants in the
Human Leukocyte Antigen (HLA) region were found to be
associated with thiopurine induced pancreatitis. Patients being
homozygous for the HLA-DQA1*02:01–HLA-DRB1*07:01
haplotype have a risk of 17% for developing pancreatitis after
thiopurine administration. Another genetic variant that confers
susceptibility to drug toxicity lies in the NUDT15 gene, which
is associated with thiopurine-induced leukopenia [96,97]. As the
genetic risk variants for severe side effects often have a large
effect size it is relatively easy to gain enough power, i.e., to col-
lect a dataset large enough, to identify them. Also the clinical
significance of these side effects is so big that testing for the
genetic risk variant before starting a drug might be feasible.
The International Serious Adverse Events Consortium (iSAEC)
together with the IIBDGC are leading the research into the
genetic background of the major side effects of IBD medical
therapy: pancreatitis through thiopurines, kidney damage
through mesalazine and neurological side-effects in anti-TNF-
alpha therapy [98].
Five-year view & expert commentary
In recent years the treatment paradigm in IBD has changed
from treating symptomatic patients to starting intensified treat-
ment regimens early in the disease to prevent complicated dis-
ease behaviour and flares of the disease [23]. However, as
Table 1. New inflammatory bowel disease drugs based on known genetic risk factors.
Potential drugs IBD risk genes targeted Effect Study status
Ustekinumab Blocking binding of IL12-IL23 Blocks the inflammatory escades down stream Effective in CD 82,83
Tofacitinib Blocking selective JAK2 inhbitor Blocking secondary pro-inflammatory
signalling after activation of the IL23 pathway
Phase III trial 84,85
mTor inhibitor ATG16L1, NOD2 and IRGM
(autophagy)
Up-regulation of the autophagy pathway Showed no efficacy 86,87
Denosumab Apoptosis regluatory gene
TNFSF11
Regulation T-cell/dendritic communication Candidate for testing therapy
88,89
This table lists new Inflammatory Bowel Disease (IBD) drugs, the genetic risk locus (indicated with their most likely candidate gene) that they target, their presumed effect
and the current status of their studies.
ATG16L1: Autophagy related 16-like 1; CD: Crohn’s disease; IL12: Interleukin 12; IL23: Interleukin 23; IRGM: Immunity-related GTPase family M protein; JAK2: Janus
kinase 2; NOD2: Nucleotide-binding oligomerization domain-containing protein 2; TNFSF11: Tumor necrosis factor (ligand) superfamily, member 11.


































































mentioned before one major clinical issue in IBD is that there
are no clinical parameters or biomarkers to predict how the dis-
ease will develop, so it is extremely difficult to identify patients
who will benefit from aggressive treatment. Another important
factor, which makes the selection of patients at risk for a severe
disease course difficult, is the extreme heterogeneity of the dis-
ease. IBD has a variety of disease subphenotypes of which
severity is difficult to classify (mild, moderate or severe disease).
It has already been established that CD patients with a severe
disease course (operations, age of onset below 40 years) carry
more genetic risk variants than CD patient with a mild disease
course [78]. But to identify genetic variants that are associated
with specific disease phenotypes or behaviour is essential to col-
lect clinical characteristics in a uniform and reproducible
manner. So far, studies for genetic associations to subpheno-
types have been performed in very small cohorts of well-
phenotyped individuals or larger cohorts of poorly pheno-
typed individuals. Hence, only genetic risk variants with a
strong risk effect have been reported to be associated to spe-
cific disease phenotypes. The NOD2 genetic risk variants
have been reported to predict severe disease course in CD
and it has been suggested that the heterogeneity of the associ-
ation signal from the HLA-region might be caused by specific
HLA variants being associated to specific subphenotypes of
IBD [16,42,99,100].
The Dutch government has funded a very large and exhaus-
tively phenotyped prospective cohort of IBD patients initiated
by the Parelsnoer Institute and the Initiative on Crohn and
Colitis (ICC). The ICC is an initiative formed by gastroenter-
ologists from all eight University Medical Centres of the Neth-
erlands. The Parelsnoer Institute, financed by the Dutch
government, is developing a biobank in which biomaterial en
phenotypical data is being collected in a uniform matter [101].
This biobank has been funded in 2007 and already contains a
large collection of both phenotype data and biomaterials. Cur-
rently, phenotype and genotype data are being integrated in an
attempt to translate the genetic findings to the clinic. We hope
that this integration of genetic and clinical data will expand
our current knowledge on biological pathways and reveal new
clinical insights.
Besides the extensively growing knowledge on the genetics
of IBD, developments in gene-sequencing technologies, as
well as increased availability of computational biology, have
lead to novel insights into the microbial composition of the
human gut microbiota. Profiling studies of the intestinal
microbiome have shown that IBD is associated with charac-
teristic shifts in the composition of the intestinal microbiota,
reinforcing the view that IBD results from altered interac-
tions between intestinal microbes and the mucosal immune
system [102,103]. Decreased complexity of the gut microbial
ecosystem is a common feature in patients with CD or
UC [9,104]. The human microbiome is a very dynamical and
interactive system. Future studies with a multifaceted
approach to the microbiome in IBD are essential. From a
clinical perspective the increased understandig of the
microbiome will hopefully lead to new treatment options like
anti- and probiotics [9,93].
Once we have established which factors predict severe disease
outcomes in IBD we might be able to start intensive treatment
early on in disease in patients with predicted severe disease and
spare patients with predicted mild disease excess treatment and
unnecessary side-effects [23].
Conclusion
In this review we have outlined the development of genetic
studies in IBD from linkage studies, via GWAS, to the Immu-
nochip study. We have discussed the shared genetic and bio-
logical background of IBD with other immune mediated
diseases. We have outlined what genetic studies have taught us
about the disease mechanisms underlying IBD. Finally we
have discussed how these findings can be translated to clinical
practice.
GWAS and the Immunochip have shown us that the under-
lying predisposition for the IBD phenotype is diminished
innate immune response followed by an exaggerated inflamma-
tory reaction to the commensal flora of the gut. However,
genetic variants by themselves explain only a small portion of
disease risk. We have to explore their interaction with environ-
mental factors and their association to specific disease pheno-
types in order to gain a comprehensive understanding of
disease mechanisms. Currently large prospective and retrospec-
tive studies are being performed focused on identifying genetic
risk variants that can predict a specific disease course, response
to therapy, or development of drug toxicity. Only through
such large well-phenotyped multi-omics studies, will we be able
to translate our knowledge on the genetic background of IBD
to clinical practice. At the outset the main benefit of translating
genetic risk variants to clinical practice will be the prediction of
drug toxicity or severe side effects from IBD therapy. The first
genetic variants predicting drug toxicity are currently being
published. In the near future we hope that our knowledge on
the genetic background of IBD can be the basis for the devel-
opment of targeted drug therapies. The process of drug reposi-
tioning based on genetic knowledge on IBD could lead to
quick wins in the development of targeted therapy, and this
venue should be persued. A final important promise that our
knowledge on the genetic background of IBD holds is that of
personalized medicine: adapting treatment to each individual
patient based on his or her genetic profile. Large studies with
multi-omics data on each patient are being performed to realise
the data integration needed in order to achieve personalized
medicine.
We hope that in a few years we can predict disease course
and best possible treatment for each patient at diagnosis with a
predictive test constructed of genetic markers, microbial
markers, protein markers and environmental factors. By this
time the range of possible IBD treatments should have
increased, and we should have a wide choice in targeted treat-
ments for severe disease, but also for the treatment of very
mild disease.
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Key issues
. Inflammatory bowel diseases (IBD), consisting of ulcerative colitis (UC) and Crohn’s disease (CD), are chronic inflammatory diseases with
a complex pathogenesis, originating from an aberrant immune response to the commensal intestinal bacterial flora in a genetically sus-
ceptible host.
. Genome-wide association studies identified 163 genetic risk variants for IBD, which account for 4,1-13,5% of disease risk variance.
. Genetic studies have led to the identification of ATG16L1, IRGM and NOD2 as CD risk genes, thus showing the importance of the
process of autophagy in CD pathogenesis.
. Almost three-quarters of the IBD genetic risk loci were found to be overlapping with other immune mediated diseases.
. The IL23 pathway has been the most extensively studied risk pathway for inflammatory disease; variants around this gene seem to give
rise to a range of different immune mediated phenotypes.
. Fine-mapping of genetic risk loci and sequencing of genetic risk loci in IBD cases and healthy controls is currently being performed and
will lead to better understanding of the causal link between the IBD associated common genetic variants and the disease mechanism.
. The newly identified IBD risk loci and biological mechanisms are suitable targets for drug therapy and several new drugs are emerging
targeting these mechanisms
. The new insights in IBD pathogenesis gained through molecular research will lead to the realization of personalized medicine: adapting
treatment to the individual patient based on his or her genetic profile.
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